Payment overview · 2025
General Payments
$204.42
9 reported records · 4 companies
Healthcare provider profile · identity verified
Maurice Vincent, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BREA, CA · NPI 1588611990
Verified facts
What the public records show
CMS Open Payments records show Maurice Vincent, M.D. received $204.42 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $78.65 | 38.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.94 | 22.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.36 | 20.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.47 | 18.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $204.42 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.87 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.46 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.94 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 116 |
| Lisinopril | Lisinopril | 296 | 89 |
| Losartan Potassium | Losartan Potassium | 261 | 80 |
| Metformin Hcl | Metformin Hcl | 208 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 36 |
| Simvastatin | Simvastatin | 178 | 56 |
| Furosemide | Furosemide | 165 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 47 |
| Gabapentin | Gabapentin | 143 | 45 |
| Omeprazole | Omeprazole | 141 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 40 |
| Ozempic | Semaglutide | 119 | 20 |
| Alprazolam | Alprazolam | 111 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 15 |
| Potassium Chloride | Potassium Chloride | 98 | 35 |
| Temazepam | Temazepam | 98 | 18 |
| Eliquis | Apixaban | 96 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 29 |
| Glipizide | Glipizide | 88 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 29 |
| Famotidine | Famotidine | 84 | 30 |
| Lorazepam | Lorazepam | 84 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 57 |
| Atenolol | Atenolol | 75 | 23 |
| Allopurinol | Allopurinol | 74 | 22 |
| Carvedilol | Carvedilol | 73 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 17 |
| Trazodone Hcl | Trazodone Hcl | 66 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 19 |
| Finasteride | Finasteride | 63 | 19 |
| Mirtazapine | Mirtazapine | 63 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 16 |
| Benazepril Hcl | Benazepril Hcl | 62 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 56 | 22 |
| Spironolactone | Spironolactone | 56 | 20 |
| Propranolol Hcl | Propranolol Hcl | 55 | 13 |
| Ibuprofen | Ibuprofen | 54 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 16 |
| Meloxicam | Meloxicam | 46 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 11 |
| Prednisone | Prednisone | 44 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 22 |
| Diazepam | Diazepam | 41 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 19 |
| Calcitriol | Calcitriol | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | 11 |
| Acyclovir | Acyclovir | 36 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 28 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 11 |
| Januvia | Sitagliptin Phosphate | 33 | 11 |
| Folic Acid | Folic Acid | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 26 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 24 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Estradiol | Estradiol | 27 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 13 |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 14 |
| Digoxin | Digoxin | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | 12 |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 14 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Humira | Adalimumab | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $204.42 · 9 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error